Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

International Journal of Environmental Research and Public Health, Год журнала: 2020, Номер 17(6), С. 2078 - 2078

Опубликована: Март 20, 2020

Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to their highly invasive nature relatively low response therapeutics. There is an absence of specific treatment strategies for this tumor subgroup, hence TNBC managed with conventional therapeutics, often leading systemic relapse. In terms histology transcription profile these cancers have similarities BRCA-1-linked cancers, it hypothesized that BRCA1 pathway non-functional type cancer. review article, we discuss the different receptors expressed by as well diversity signaling pathways targeted example, Notch, Hedgehog, Wnt/b-Catenin TGF-beta pathways. Additionally, many epidermal growth factor (EGFR), poly (ADP-ribose) polymerase (PARP) mammalian rapamycin (mTOR) inhibitors effectively inhibit TNBCs, but they face challenges either resistance drugs or The agents has helped advancement advanced approaches including hyperthermia, photodynamic therapy, nanomedicine-based therapeutics drugs, miRNA, siRNA, aptamers, which will also be discussed. Artificial intelligence another tool presented enhance diagnosis TNBC.

Язык: Английский

---

Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer

Cancer Research, Год журнала: 2015, Номер 76(1), С. 62 - 72

Опубликована: Ноя. 14, 2015

Abstract Resistance to therapy and lack of curative treatments for metastatic breast cancer suggest that current therapies may be missing the subpopulation chemoresistant radioresistant stem cells (CSC). The ultimate success any treatment well rest on CSC eradication, but specific anti-CSC are still limited. A comparison transcriptional profiles murine Her2+ tumor TUBO their derived CSC-enriched tumorspheres has identified xCT, functional subunit cystine/glutamate antiporter system xc−, as a surface protein is upregulated specifically in tumorspheres. We validated this finding by cytofluorimetric analysis immunofluorescence TUBO-derived panel mouse human triple negative cell-derived further show downregulation xCT impaired tumorsphere generation altered intracellular redox balance vitro, suggesting plays role biology. DNA vaccination based immunotargeting mice challenged with syngeneic tumorsphere-derived delayed established subcutaneous growth strongly pulmonary metastasis formation generating anti-xCT antibodies able alter self-renewal balance. Finally, increased chemosensitivity doxorubicin vivo, indicating an effective adjuvant chemotherapy. Cancer Res; 76(1); 62–72. ©2015 AACR.

Язык: Английский

---

In vivo relevant mixed urolithins and ellagic acid inhibit phenotypic and molecular colon cancer stem cell features: A new potentiality for ellagitannin metabolites against cancer

Food and Chemical Toxicology, Год журнала: 2016, Номер 92, С. 8 - 16

Опубликована: Март 16, 2016

Язык: Английский

---

Targeting cancer stem‐like cells in glioblastoma and colorectal cancer through metabolic pathways

International Journal of Cancer, Год журнала: 2016, Номер 140(1), С. 10 - 22

Опубликована: Июль 8, 2016

Cancer stem-like cells (CSCs) are thought to be the main cause of tumor occurrence, progression and therapeutic resistance. Strong research efforts in last decade have led development several tailored approaches target CSCs with some very promising clinical trials underway; however, until now no anti-CSC therapy has been approved for use. Given recent improvement our understanding how onco-proteins can manipulate cellular metabolic networks promote tumorigenesis, cancer metabolism may well lead innovative strategies identify novel regulators downstream mediators CSC maintenance. Interfering distinct stages CSC-associated metabolics elucidate novel, more efficient this highly malignant cell population. Here discoveries regarding properties attributed glioblastoma (GBM) colorectal (CRC) were summarized. The association between stem markers, response hypoxia other environmental stresses including insults as developmentally conserved signaling pathways alterations bioenergetic also discussed. developments imaging This summary should comprehensively update basic scientists on traits GBM CRC.

Язык: Английский

---

Cancer stem cells: at the forefront of personalized medicine and immunotherapy

Current Opinion in Pharmacology, Год журнала: 2017, Номер 35, С. 1 - 11

Опубликована: Май 18, 2017

Язык: Английский

---

Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition

Oncotarget, Год журнала: 2015, Номер 6(33), С. 35023 - 35039

Опубликована: Сен. 16, 2015

// Fang Wei 1, 6, * , Xiao-Xiang Rong 3, Rao-Ying Xie Li-Ting Jia 5 Hui-Yan Wang 1 Yu-Juan Qin Lin Chen Hong-Fen Shen Xiao-Lin Jie Yang Sheng Wei-Chao Hao Yan Sheng-Jun Xiao Hui-Rong Zhou Tao-Yan Yu-Shuang Sun 4 Kai-Tai Yao Dong 2 Cancer Research Institute, Southern Medical University, Guangzhou 510515, China Institute of Comparative Medicine & Laboratory Animal Center, 3 Department Oncology, Nanfang Hospital, Children's Hospital Boston, Harvard School, Massachusetts 02115, USA Pathology, Guilin College, 541001, 6 Digestive Disease First People's 510180, These authors have contributed equally to this work Correspondence to: Xiao, e-mail: [email protected] Yao, [email protected] Keywords: nasopharyngeal carcinoma, cytokine-induced killer cells, cancer stem promoter-reporter gene strategy, time-lapse imaging Received: May 27, 2015      Accepted: September 04, Published: 16, 2015 ABSTRACT cells (CSCs) are considered be the root cause for treatment failure. Thus, there remains an urgent need more potent and safer therapies against CSCs curing cancer. In study, antitumor activity (CIK) putative carcinoma (NPC) was fully evaluated in vitro vivo . To visualize by fluorescence imaging, image quantify tumor xenograft-bearing mice bioluminescence NPC were engineered with CSC detector vector encoding GFP luciferase (Luc) under control Nanog promoter. Our study reported intense tumor-killing CIK NPC, as revealed percentage analysis side population tumorsphere formation assay Nanog-promoter-GFP-Luc reporter strategy plus recording. Additionally, firstly illustrated that GFP-labeled or PKH26-labeled tumorspheres usually attacked simultaneously many finally killed suggesting necessity achieving sufficient effector-to-target ratios. We confirmed NKG2D blockade anti-NKG2D antibody significantly but partially abrogated cell-mediated cytolysis CSCs. More importantly, intravenous infusion delayed growth NOD/SCID mice, accompanied a remarkable reduction number monitored whole-body imaging. Taken together, our findings suggest demonstrate at least part, NKG2D-ligands recognition. results indicate cell-based therapeutic presents promising safe approach treatment.

Язык: Английский

---

Update on immune‐based therapy strategies targeting cancer stem cells

Cancer Medicine, Год журнала: 2023, Номер 12(18), С. 18960 - 18980

Опубликована: Сен. 1, 2023

Abstract Accumulating data reveals that tumors possess a specialized subset of cancer cells named stem (CSCs), responsible for metastasis and recurrence malignancies, with various properties such as self‐renewal, heterogenicity, capacity drug resistance. Some signaling pathways or processes like Notch, epithelial to mesenchymal transition (EMT), Hedgehog (Hh), Wnt, well CSCs' surface markers CD44, CD123, CD133, cell adhesion molecule (EpCAM) have pivotal roles in acquiring CSCs properties. Therefore, targeting CSC‐related might effectively eradicate pave the way survival. Since current treatments chemotherapy radiation therapy cannot all tumor relapse may happen following temporary recovery, improving novel more efficient therapeutic options combine is required. Immunotherapy strategies are new modalities promising results CSCs. Here, we review by immunotherapy dendritic (DC) vaccines, chimeric antigen receptors (CAR)‐engineered immune cells, natural killer‐cell (NK‐cell) therapy, monoclonal antibodies (mAbs), checkpoint inhibitors, use oncolytic viruses (OVs) pre‐clinical clinical studies. This will mainly focus on blood malignancies but also describe solid cancers.

Язык: Английский

---

LAG-3 and TIM-3 expression in melanoma and histopathological correlation: a single-center study

Clinical & Translational Oncology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 3, 2025

Язык: Английский

---

Novel Therapeutic Strategies and Recent Advances in Gut Microbiota Synergy with Nanotechnology for Colorectal Cancer Treatment

Materials Today Bio, Год журнала: 2025, Номер 31, С. 101601 - 101601

Опубликована: Фев. 20, 2025

Over the last two decades, molecular biology advances have revealed gut microbiota's active and crucial role in colorectal cancer (CRC) pathogenesis its dysregulation during tumorigenesis. This understanding has underscored urgency of exploring novel therapeutic approaches to address challenges posed by CRC. Among these approaches, nanosynergistic therapies, with their potential modulate microbiota, increase drug bioavailability stability, reduce side effects, emerged as a promising avenue. Furthermore, efficacy nanotechnology-based can be enhanced combining them different methods, including chemotherapy, radiotherapy, immunotherapy, photothermal therapy, sonodynamic therapy. Herein, recent progress nano synergistic therapy been reviewed, focusing on synergy between microbiota nanotechnology CRC treatment. Additionally, diverse applications nanoparticles analyzed provide innovative ideas effective solutions for developing highly treatment strategies.

Язык: Английский

---

Cancer Bioenergetics and Tumor Microenvironments—Enhancing Chemotherapeutics and Targeting Resistant Niches through Nanosystems

Cancers, Год журнала: 2023, Номер 15(15), С. 3836 - 3836

Опубликована: Июль 28, 2023

Cancer is an impending bottleneck in the advanced scientific workflow to achieve diagnostic, prognostic, and therapeutic success. Most cancers are refractory conventional diagnostic chemotherapeutics due their limited targetability, specificity, solubility, side effects. The inherent ability of each cancer evolve through various genetic epigenetic transformations metabolic reprogramming underlies limitations. Though tumor microenvironments (TMEs) quite well understood some cancers, microenvironment differs from other internal perturbations skew thereby impeding development appropriate diagnostics, drugs, vaccines, therapies. associated bioenergetics modulations regulate TME, angiogenesis, immune evasion, generation resistant niches progression, a thorough understanding crucial However, this remains missing element theranostics, necessitating modalities that can be adapted for diagnostics therapeutics. In challenging scenario, nanomaterials modular platforms TME achieving successful theranostics. Several nanoscale particles have been successfully researched animal models, few reached clinical trials, achieved Nanoparticles exhibit intrinsic capability interact with diverse biomolecules modulate functions. Furthermore, nanoparticles functionalized receptors, modulators, drugs facilitate specific targeting reduced toxicity. This review discusses current different theranostic nanosystems, synthesis, functionalization, targetability modulation bioenergetics, microenvironment. We highlight potential nanosystems enhanced chemotherapeutic success emphasizing questions remain unanswered.

Язык: Английский

---